IL17A and psoriasis: A recent systematic review and meta‐analysis of 69 real‐world cohort studies aggregating drug survival outcomes of 48,704 psoriasis patients on IL‐23 and IL‐17 inhibitors revealed high drug survival rates, with the highest rates for guselkumab and risankizumab as seen in our study.24